Concepedia

David Holmes

DH

21

Publications

2.3K

Citations

16

H-Index

1983

Active since

Affiliations

Novartis (Switzerland)(Current)

University at Buffalo, State University of New York

Umeå University

University of Gothenburg

Lund University

David Holmes is an author at Novartis (Switzerland) specializing in information retrieval, engineering, and medicine.

ORCID

Top concepts

Publications per year

1983–2020

21

Publications

21

Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

Bo Åhrén, Mona Landin‐Olsson, Per‐Anders Jansson et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 711 citations

, , +18

Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes

Bo Åhrén, Erik Simonsson, Hillevi Larsson et al. · Diabetes Care · 2002 · 423 citations · Full text

Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

Smiljana Ristič, S. Byiers, James E. Foley et al. · Diabetes Obesity and Metabolism · 2005 · 249 citations

Twelve-week Monotherapy with the DPP-4 Inhibitor Vildagliptin Improves Glycemic Control in Subjects with Type 2 Diabetes

Richard E. Pratley, S. Jauffret-Kamel, Elizabeth J. Galbreath et al. · Hormone and Metabolic Research · 2006 · 193 citations

The Dipeptidyl Peptidase 4 Inhibitor Vildagliptin Does Not Accentuate Glibenclamide-Induced Hypoglycemia but Reduces Glucose-Induced Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide Secretion

A. El-Ouaghlidi, Erika Rehring, Jens J. Holst et al. · The Journal of Clinical Endocrinology & Metabolism · 2007 · 115 citations · Full text

Rows per page

1–5 of 21